Administration of resveratrol to prevent or treat restenosis following coronary intervention
US6211247A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Nov 4, 1999 |
| Grant date | Apr 3, 2001 |
| Priority date | — |
| Expiry date | Nov 4, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for preventing or treating restenosis and for preventing the recurrence or progression of coronary heart disease is provided. The method involves administration of a selected active agent to a patient following coronary intervention, e.g., coronary artery bypass surgery, endarterectomy, heart transplantation, heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting. The active agent comprises cis-resveratrol, trans-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. Administration may be oral, parenteral, or the like. Pharmaceutical compositions for use in conjunction with the therapeutic method are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.